10 minute read
Oct. 11, 2023

The Highly Potent and CNS-Active NX-5948 Shows BTK Degradation in Patients


oral BTK degrader Ph. I for B-cell malignancies from degrader screening First Disclosures, ACS Fall 2023 Nurix Therapeutics, San Francisco, CA


Molecules of the Month - August 2023

MOTY Nominees

Molecule of the Year